Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

Related Articles by Review for PubMed (Select 20679598)

1.

Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.

Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, O'Brien M, Eby M, Cole DE, Murphy RF, Fox E, Ivy P, Adamson PC.

J Clin Oncol. 2010 Sep 1;28(25):3979-86. doi: 10.1200/JCO.2009.25.4540. Epub 2010 Aug 2.

2.

Glucarpidase for the treatment of life-threatening methotrexate overdose.

Tuffaha HW, Al Omar S.

Drugs Today (Barc). 2012 Nov;48(11):705-11. doi: 10.1358/dot.2012.48.11.1871575. Review.

PMID:
23170306
3.

Glucarpidase following high-dose methotrexate: update on development.

Patterson DM, Lee SM.

Expert Opin Biol Ther. 2010 Jan;10(1):105-11. doi: 10.1517/14712590903468677. Review.

PMID:
19925307
4.

Understanding and managing methotrexate nephrotoxicity.

Widemann BC, Adamson PC.

Oncologist. 2006 Jun;11(6):694-703. Review.

5.

Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.

Fermiano M, Bergsbaken J, Kolesar JM.

Am J Health Syst Pharm. 2014 May 15;71(10):793-8. doi: 10.2146/ajhp130483. Review.

PMID:
24780487
6.

Concepts in use of high-dose methotrexate therapy.

Treon SP, Chabner BA.

Clin Chem. 1996 Aug;42(8 Pt 2):1322-9. Review.

7.

High-dose methotrexate: a critical reappraisal.

Ackland SP, Schilsky RL.

J Clin Oncol. 1987 Dec;5(12):2017-31. Review.

PMID:
3316519
8.

[Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].

Cózar Olmo JA, Martínez Colmenero C, Peláez Pleguezuelos I, Leiva Gea I, López García AB, de la Cruz Moreno J.

An Pediatr (Barc). 2009 Sep;71(3):230-4. doi: 10.1016/j.anpedi.2009.05.014. Epub 2009 Jul 18. Review. Spanish.

9.

High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?

Sterba J, Valík D, Bajciová V, Kadlecová V, Gregorová V, Mendelová D.

Neoplasma. 2005;52(6):456-63. Review.

PMID:
16284689
10.

Glucarpidase Intervention for Delayed Methotrexate Clearance.

Cavone JL, Yang D, Wang A.

Ann Pharmacother. 2014 Apr 17;48(7):897-907. [Epub ahead of print] Review.

PMID:
24742398
11.

Glucarpidase (Voraxaze) for methotrexate toxicity.

[No authors listed]

Med Lett Drugs Ther. 2012 Mar 5;54(1385):19-20. Review. No abstract available.

PMID:
22382581
12.

Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.

Browman GP, Goodyear MD, Levine MN, Russell R, Archibald SD, Young JE.

J Clin Oncol. 1990 Feb;8(2):203-8. Review.

PMID:
2405105
13.

Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).

Cohen IJ.

Med Hypotheses. 2013 Nov;81(5):942-7. doi: 10.1016/j.mehy.2013.08.027. Epub 2013 Sep 3. Review.

PMID:
24035689
14.

How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity?

Cohen IJ, Wolff JE.

Pediatr Blood Cancer. 2014 Jan;61(1):7-10. doi: 10.1002/pbc.24770. Epub 2013 Sep 13. Review.

PMID:
24038885
15.

What is the best therapy for toxicity in the setting of methotrexate-associated acute kidney injury: high-flux hemodialysis or carboxypeptidase G2?

Kumar N, Shirali AC.

Semin Dial. 2014 May-Jun;27(3):226-8. doi: 10.1111/sdi.12220. Epub 2014 Mar 13. Review. No abstract available.

PMID:
24620824
16.

Successful use of intrathecal carboxypeptidase G2 for intrathecal methotrexate overdose: a case study and review of the literature.

Bradley AM, Buie LW, Kuykendal A, Voorhees PM.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):166-70. doi: 10.1016/j.clml.2012.09.004. Epub 2012 Oct 17. Review. No abstract available.

PMID:
23084403
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk